Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 1.1.1.2 - alcohol dehydrogenase (NADP+)

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acidosis
Ethanol metabolism, cirrhosis and alcoholism.
Acute Kidney Injury
Changes in 25-hydroxyvitamin D3 alpha- and 24-hydroxylase activities of kidney cells isolated from rats with either unilateral kidney damage or acute renal insufficiency.
Adenocarcinoma
Cancer biomarker AKR1B10 and carbonyl metabolism.
Adenocarcinoma of Lung
Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
Structure and promoter characterization of aldo-keto reductase family 1 B10 gene.
Adrenocortical Carcinoma
Homeobox A5 activates p53 pathway to inhibit proliferation and promote apoptosis of adrenocortical carcinoma cells by inducing Aldo-Keto reductase family 1 member B10 expression.
Arthritis
Effect of adjuvant polyarthritis on liver alcohol dehydrogenase in the rat.
Ascorbic Acid Deficiency
Vitamin C. Biosynthesis, recycling and degradation in mammals.
Astrocytoma
[Effect of AKR1A1 knock-down on H2;O2; and 4-hydroxynonenal-induced cytotoxicity in human 1321N1 astrocytoma cells].
Breast Neoplasms
AKR1B1 promotes basal-like breast cancer progression by a positive feedback loop that activates the EMT program.
AKR1B10 activates diacylglycerol (DAG) second messenger in breast cancer cells.
AKR1B10 promotes breast cancer cell migration and invasion via activation of ERK signaling.
AKR1B10 promotes breast cancer cell proliferation and migration via the PI3K/AKT/NF-?B signaling pathway.
Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells.
Alterations in estrogen signalling pathways upon acquisition of anthracycline resistance in breast tumor cells.
An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies.
Bioequivalence studies of tibolone in premenopausal women and effects on expression of the tibolone-metabolizing enzyme AKR1C (aldo-keto reductase) family caused by estradiol.
Oncogenic EP300 can be targeted with inhibitors of aldo-keto reductases.
Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer.
Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.
SMAR1 regulates free radical stress through modulation of AKR1a4 enzyme activity.
Carcinogenesis
Adrenal tumorigenesis targeted by the corticotropin-regulated promoter of the aldo-keto reductase AKR1B7 gene in transgenic mice.
Aldo-Keto Reductase Regulation by the Nrf2 System: Implications for Stress Response, Chemotherapy Drug Resistance, and Carcinogenesis.
Expression of AKR1B10 as an independent marker for poor prognosis in human oral squamous cell carcinoma.
Low expression of Aldo-keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma.
Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.
Overexpression of AKR1B10 predicts tumor recurrence and short survival in oral squamous cell carcinoma patients.
Sulindac inhibits pancreatic carcinogenesis in LSL-KrasG12D-LSL-Trp53R172H-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10).
Carcinoma
Activation of polycyclic aromatic hydrocarbon trans-dihydrodiol proximate carcinogens by human aldo-keto reductase (AKR1C) enzymes and their functional overexpression in human lung carcinoma (A549) cells.
AKR1B10 confers resistance to radiotherapy via FFA/TLR4/NF-?B axis in nasopharyngeal carcinoma.
AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group.
Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells.
Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer.
Down-regulation of aldo-keto reductase AKR1B10 gene expression by a phorbol ester via the ERK/c-Jun signaling pathway.
Effect of nicotinamide on hepatic microsomal drug metabolising system in tumour-bearing rats and mice.
Increased salivary AKR1B10 level: Association with progression and poor prognosis of oral squamous cell carcinoma.
Knockdown or inhibition of aldo-keto reductase 1B10 inhibits pancreatic carcinoma growth via modulating Kras-E-cadherin pathway.
Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity.
Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.
Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas.
The Expression and Clinical Significance of Aldo-Keto Reductase 1 Member B1 in Gastric Carcinoma.
Carcinoma, Ductal
Overexpression of Aldo-keto reductase family 1 B10 protein in ductal carcinoma in situ of the breast correlates with HER2 positivity.
Carcinoma, Embryonal
Characterization of the functional gene encoding mouse class III alcohol dehydrogenase (glutathione-dependent formaldehyde dehydrogenase) and an unexpressed processed pseudogene with an intact open reading frame.
The role of alcohol dehydrogenase in retinoic acid homeostasis and fetal alcohol syndrome.
Carcinoma, Hepatocellular
A Large-Scale Multicenter Study Validates AKR1B10 as a New Prevalent Serum Marker for Detection of Hepatocellular Carcinoma.
Abnormal membrane phospholipid content in subcellular fractions from the Morris 7777 hepatoma.
AKR1B10 expression by immunohistochemistry in surgical resections and fine needle aspiration cytology material in patients with cystic pancreatic lesions; potential for improved nonoperative diagnosis.
AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases.
Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells.
Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) overexpression in tumors predicts worse overall survival in hepatocellular carcinoma.
Aldo-keto reductase family 1 member B10 is associated with hepatitis B virus-related hepatocellular carcinoma risk.
Bioequivalence studies of tibolone in premenopausal women and effects on expression of the tibolone-metabolizing enzyme AKR1C (aldo-keto reductase) family caused by estradiol.
Dietary Se deficiency dysregulates metabolic and cell death signaling in aggravating the AFB1 hepatotoxicity of chicks.
Down-regulation of aldo-keto reductase AKR1B10 gene expression by a phorbol ester via the ERK/c-Jun signaling pathway.
Expression of aldo-keto reductase family 1 member b10 in the early stages of human hepatocarcinogenesis.
Expression of differentiated functions in hepatoma cell hybrids. VI. Extinction and re-expression of liver alcohol dehydrogenase.
High expression of AKR1B10 predicts low risk of early tumor recurrence in patients with hepatitis B virus-related hepatocellular carcinoma.
High expression of aldo-keto reductase 1B10 is an independent predictor of favorable prognosis in patients with hepatocellular carcinoma.
Identification of a role for serum aldo-keto reductase family 1 member B10 in early detection of hepatocellular carcinoma.
Immunohistochemistry Detects Increased Expression of Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) in Early-Stage Hepatocellular Carcinoma.
Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma.
Induction of alcohol dehydrogenase activity and mRNA in hepatoma cells by dexamethasone.
Metabolic enzyme induction by HepG2 cells exposed to oxygenated and nonoxygenated polycyclic aromatic hydrocarbons.
Metabolism of gamma hydroxybutyrate in human hepatoma HepG2 cells by the aldo-keto reductase AKR1A1.
New data on kinetics of lipid peroxidation in experimental hepatomas and preneoplastic nodules.
Prognostic Significance of 14-3-3?, Aldo-keto Reductase Family 1 B10 and Metallothionein-1 in Hepatocellular Carcinoma.
Proteome analysis of rat hepatomas: carcinogen-dependent tumor-associated protein variants.
Purification and catalytic properties of liver alcohol dehydrogenase isoenzymes in patients with hepatoma in Nigeria.
Quantitative Evaluation of Aldo-keto Reductase Expression in Hepatocellular Carcinoma (HCC) Cell Lines.
Regulation Network and Prognostic Significance of Aldo-Keto Reductase (AKR) Superfamily Genes in Hepatocellular Carcinoma.
Structure and promoter characterization of aldo-keto reductase family 1 B10 gene.
Studies on lipid peroxidation in normal and tumour tissues. The Yoshida rat liver tumour.
Up-regulated aldo-keto reductase family 1 member B10 in chronic hepatitis C: association with serum alpha-fetoprotein and hepatocellular carcinoma.
[Aldo-keto reductase family 1 B10 participates in the regulation of hepatoma cell cycle through p27/p-Rb signaling pathway].
[Enzymes metabolizing xenobiotics in spontaneous tumors in mice]
Carcinoma, Intraductal, Noninfiltrating
Overexpression of Aldo-keto reductase family 1 B10 protein in ductal carcinoma in situ of the breast correlates with HER2 positivity.
Carcinoma, Non-Small-Cell Lung
Activation of polycyclic aromatic hydrocarbon trans-dihydrodiol proximate carcinogens by human aldo-keto reductase (AKR1C) enzymes and their functional overexpression in human lung carcinoma (A549) cells.
Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells.
Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer.
Carcinoma, Ovarian Epithelial
Computational design of novel peptidomimetic inhibitors of cadherin homophilic interactions.
Carcinoma, Squamous Cell
Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity.
Structure and promoter characterization of aldo-keto reductase family 1 B10 gene.
Cardiotoxicity
Development of a CART Model to Predict the Synthesis of Cardiotoxic Daunorubicinol in Heart Tissue Samples From Donors With and Without Down Syndrome.
Cataract
Effect of C7 Modifications on Benzothiadiazine-1,1-dioxide Derivatives on Their Inhibitory Activity and Selectivity toward Aldose Reductase.
Cell Transformation, Neoplastic
AKR1B10 overexpression in breast cancer: Association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker.
Chagas Disease
A role for trypanosomatid aldo-keto reductases in methylglyoxal, prostaglandin and isoprostane metabolism.
Colitis, Ulcerative
Impaired Barrier Function and Immunity in the Colon of Aldo-Keto Reductase 1B8 Deficient Mice.
Colonic Neoplasms
Evaluation of an aldo-keto reductase gene signature with prognostic significance in colon cancer via activation of epithelial to mesenchymal transition and the p70S6K pathway.
Expression of AKR1C3 and CNN3 as markers for detection of lymph node metastases in colorectal cancer.
Inhibition of aldose reductase prevents angiogenesis in vitro and in vivo.
Significance of aldo-keto reductase 1C3 and ATP-binding cassette transporter B1 in gain of irinotecan resistance in colon cancer cells.
Transcriptional regulation of aldo-keto reductase 1C1 in HT29 human colon cancer cells resistant to methotrexate: role in the cell cycle and apoptosis.
Colorectal Neoplasms
Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
Expression of AKR1C3 and CNN3 as markers for detection of lymph node metastases in colorectal cancer.
Impaired Barrier Function and Immunity in the Colon of Aldo-Keto Reductase 1B8 Deficient Mice.
Impaired Self-Renewal and Increased Colitis and Dysplastic Lesions in Colonic Mucosa of AKR1B8-Deficient Mice.
Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib.
Dehydration
Stopped-flow determination of the active form of acetaldehyde in the liver alcohol dehydrogenase catalyzed reaction.
Dementia
Loss of endoplasmic reticulum-associated enzymes in affected brain regions in Huntington's disease and Alzheimer-type dementia.
Diabetes Complications
Aldo-keto reductase and sorbitol dehydrogenase enzymes in Egyptian diabetic patients with and without proliferative diabetic retinopathy.
Aldo-Keto Reductase Family 1 B1 Inhibitors: Old Drugs with New Perspectives.
Cooperative regulation of mouse aldose reductase (AKR1B3) gene transcription by Nrf2, TonEBP, and c-jun.
Expression of human aldose and aldehyde reductases. Site-directed mutagenesis of a critical lysine 262.
Functional genomic studies of aldo-keto reductases.
High-resolution neutron protein crystallography with radically small crystal volumes: application of perdeuteration to human aldose reductase.
Kinetic and structural characterization of the glutathione-binding site of aldose reductase.
Reductive detoxification of acrolein as a potential role for aldehyde reductase (AKR1A) in mammals.
The hop-derived compounds xanthohumol, isoxanthohumol and 8-prenylnaringenin are tight-binding inhibitors of human aldo-keto reductases 1B1 and 1B10.
Transcript Levels of Aldo-Keto Reductase Family 1 Subfamily C (AKR1C) Are Increased in Prostate Tissue of Patients with Type 2 Diabetes.
Diabetes Mellitus
Renal gene expression in embryonic and newborn diabetic mice.
Targeting aldose reductase for the treatment of diabetes complications and inflammatory diseases: new insights and future directions.
Diabetes Mellitus, Experimental
[Status of the monooxygenase enzyme system in rat and rabbit organs in sugar diabetes and upon insulin administration]
Diabetes Mellitus, Type 2
Transcript Levels of Aldo-Keto Reductase Family 1 Subfamily C (AKR1C) Are Increased in Prostate Tissue of Patients with Type 2 Diabetes.
Diabetic Nephropathies
Relevance of aldo-keto reductase family members to the pathobiology of diabetic nephropathy and renal development.
Diabetic Retinopathy
Aldo-keto reductase and sorbitol dehydrogenase enzymes in Egyptian diabetic patients with and without proliferative diabetic retinopathy.
Digestive System Neoplasms
Prognostic value of aldo-keto reductase family 1 member B10 (AKR1B10) in digestive system cancers: A meta-analysis.
Down Syndrome
Development of a CART Model to Predict the Synthesis of Cardiotoxic Daunorubicinol in Heart Tissue Samples From Donors With and Without Down Syndrome.
Drug Hypersensitivity
Variability of the Genes Involved in the Cellular Redox Status and Their Implication in Drug Hypersensitivity Reactions.
Endometrial Neoplasms
Decreased levels of AKR1B1 and AKR1B10 in cancerous endometrium compared to adjacent non-cancerous tissue.
Discovery of new inhibitors of aldo-keto reductase 1C1 by structure-based virtual screening.
Epilepsy
Discovery of new inhibitors of aldo-keto reductase 1C1 by structure-based virtual screening.
Fatty Liver
Ethanol metabolism, cirrhosis and alcoholism.
Fibrosarcoma
Effect of nicotinamide on hepatic microsomal drug metabolising system in tumour-bearing rats and mice.
Gastrointestinal Neoplasms
Aldo-keto reductase 1B10 promotes development of cisplatin resistance in gastrointestinal cancer cells through down-regulating peroxisome proliferator-activated receptor-?-dependent mechanism.
Glioblastoma
Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression.
Hepatitis B
Aldo-keto reductase family 1 member B10 is associated with hepatitis B virus-related hepatocellular carcinoma risk.
High expression of AKR1B10 predicts low risk of early tumor recurrence in patients with hepatitis B virus-related hepatocellular carcinoma.
Hepatitis C
Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma.
Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication.
Hepatitis C, Chronic
Up-regulated aldo-keto reductase family 1 member B10 in chronic hepatitis C: association with serum alpha-fetoprotein and hepatocellular carcinoma.
Hepatoblastoma
A nuclear protein, synthesized in growth-arrested human hepatoblastoma cells, is a novel member of the short-chain alcohol dehydrogenase family.
Huntington Disease
Loss of endoplasmic reticulum-associated enzymes in affected brain regions in Huntington's disease and Alzheimer-type dementia.
Hyperglycemia
Ethanol metabolism, cirrhosis and alcoholism.
Hyperthyroidism
Thyroid hormone action on intermediary metabolism. Part III. Protein metabolism in hyper- and hypothyroidism.
Hypoglycemia
[Status of the monooxygenase enzyme system in rat and rabbit organs in sugar diabetes and upon insulin administration]
Infections
Drug metabolism in experimental tuberculosis: I. Changes in hepatic and pulmonary monooxygenase activities due to infection.
Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma.
Infection of barley with the parasitic fungus Blumeria graminis f.sp. hordei results in the induction of HvADH1 and HvADH2.
Rat liver alcohol dehydrogenase isozymes: influence of infection with Trypanosoma.
Influenza, Human
QSAR models based on quantum topological molecular similarity.
Quantum topological QSAR models based on the MOLMAP approach.
Keloid
The aldo-keto reductase AKR1B10 is upregulated in keloid epidermis, implicating retinoic acid pathway dysregulation in the pathogenesis of keloid disease.
Leukemia
Characterization of daunorubicin resistance in K562 leukemia cells lacking daunorubicin reductase activity.
Daunorubicin reductase activity in leukemia leukocyte homogenates.
High-dose daunorubicin therapy for acute nonlymphocytic leukemia: correlation of response and toxicity with pharmacokinetics and intracellular daunorubicin reductase activity.
Methyl Jasmonate: Putative Mechanisms of Action on Cancer Cells Cycle, Metabolism, and Apoptosis.
Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-?-hydroxysteroid dehydrogenase (AKR1C3).
Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3.
The monocytic differentiation of HL60 induced by rat kidney NADPH-linked high-Km aldehyde reductase protein.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Aldo-keto reductase inhibitors increase the anticancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia.
Leukemia, Myeloid
The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs.
Leukemia, Myeloid, Acute
High-dose daunorubicin therapy for acute nonlymphocytic leukemia: correlation of response and toxicity with pharmacokinetics and intracellular daunorubicin reductase activity.
Hypoxia triggers major metabolic changes in AML cells without altering indomethacin-induced TCA cycle deregulation.
Upregulation of AKR1C1 in mesenchymal stromal cells promotes the survival of acute myeloid leukaemia cells.
Lipedema
Aldo-Keto Reductase 1C1 (AKR1C1) as the First Mutated Gene in a Family with Nonsyndromic Primary Lipedema.
Liver Cirrhosis
Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis.
Liver Cirrhosis, Alcoholic
Alterations of liver alcohol dehydrogenase and other hepatic enzymes in alcoholic cirrhosis.
Polymorphism of alcohol dehydrogenase, alcohol and aldehyde dehydrogenase activities: implication in alcoholic cirrhosis in white patients. The French Group for Research on Alcohol and Liver.
Liver Diseases
Aldo-keto reductase family 1 member B10 is associated with hepatitis B virus-related hepatocellular carcinoma risk.
Genetic polymorphism of liver alcohol dehydrogenase in Spanish subjects: significance of alcohol consumption and liver disease.
Immunohistochemistry Detects Increased Expression of Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) in Early-Stage Hepatocellular Carcinoma.
Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma.
Influence of liver disease and environmental factors on hepatic monooxygenase activity in vitro.
Monooxygenase enzyme activity in alcoholics with varying degrees of liver damage.
Liver Diseases, Alcoholic
Atypical liver alcohol dehydrogenase in the Spanish population: its relation with the development of alcoholic liver disease.
Liver Neoplasms
A novel AKR1C3 specific prodrug TH3424 with potent anti-tumor activity in liver cancer.
AKR1B10 (Aldo-keto reductase family 1 B10) promotes brain metastasis of lung cancer cells in a multi-organ microfluidic chip model.
Aldo-keto Reductase Family 1 Member B 10 Mediates Liver Cancer Cell Proliferation through Sphingosine-1-Phosphate.
Cancer biomarker AKR1B10 and carbonyl metabolism.
Lung Neoplasms
AKR1B10 (Aldo-keto reductase family 1 B10) promotes brain metastasis of lung cancer cells in a multi-organ microfluidic chip model.
Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls.
Correction to Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy against Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer Cells.
Exposure to 9,10-phenanthrenequinone accelerates malignant progression of lung cancer cells through up-regulation of aldo-keto reductase 1B10.
Inhibiting proliferation and migration of lung cancer using small interfering RNA targeting on Aldo-keto reductase family 1 member B10.
Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids.
Nitric oxide confers cisplatin resistance in human lung cancer cells through upregulation of aldo-keto reductase 1B10 and proteasome.
Protective roles of aldo-keto reductase 1B10 and autophagy against toxicity induced by p-quinone metabolites of tert-butylhydroquinone in lung cancer A549 cells.
Roles of aldo-keto reductase 1B10 and 1C3 and ATP-binding cassette transporter in docetaxel tolerance.
Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy against Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer Cells.
Melanoma
A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma.
Prospective Multicenter Phase II Trial of Systemic ADH-1 in Combination With Melphalan via Isolated Limb Infusion in Patients With Advanced Extremity Melanoma.
Mesothelioma, Malignant
Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma.
Multiple Myeloma
LCRF-0006, a small molecule mimetic of the N-cadherin antagonist peptide ADH-1, synergistically increases multiple myeloma response to bortezomib.
Nasopharyngeal Carcinoma
Low expression of Aldo-keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma.
Neoplasm Metastasis
ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression.
AKR1B10 activates diacylglycerol (DAG) second messenger in breast cancer cells.
AKR1B10 promotes breast cancer cell proliferation and migration via the PI3K/AKT/NF-?B signaling pathway.
Correction to Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy against Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer Cells.
Expression of AKR1C3 and CNN3 as markers for detection of lymph node metastases in colorectal cancer.
Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation.
Novel peptide mimetic small molecules of the HAV motif in N-cadherin inhibit N-cadherin-mediated neurite outgrowth and cell adhesion.
Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy against Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer Cells.
Neoplasms
A therapeutic method for the direct reprogramming of human liver cancer cells with only chemicals.
ADH-1 in the treatment of metastatic adrenocortical carcinoma--case report.
ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression.
AKR1B10 (Aldo-keto reductase family 1 B10) promotes brain metastasis of lung cancer cells in a multi-organ microfluidic chip model.
AKR1B10 activates diacylglycerol (DAG) second messenger in breast cancer cells.
AKR1B10 promotes breast cancer cell migration and invasion via activation of ERK signaling.
AKR1B10 promotes breast cancer cell proliferation and migration via the PI3K/AKT/NF-?B signaling pathway.
AKR1B10 promotes breast cancer metastasis through integrin ?5/?-catenin mediated FAK/Src/Rac1 signaling pathway.
AKR1B10-inhibitory Selaginella tamariscina extract and amentoflavone decrease the growth of A549 human lung cancer cells in vitro and in vivo.
AKR1C enzymes sustain therapy resistance in paediatric T-ALL.
AKR1C isoforms represent a novel cellular target for jasmonates alongside their mitochondrial-mediated effects.
AKR1C3 Is Associated with Better Survival of Patients with Endometrial Carcinomas.
Aldo-Keto Reductase 1B10 and Its Role in Proliferation Capacity of Drug-Resistant Cancers.
Aldo-keto reductase 1C1 induced by interleukin-1? mediates the invasive potential and drug resistance of metastatic bladder cancer cells.
Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN Loss.
Aldo-Keto Reductase Family 1 B1 Inhibitors: Old Drugs with New Perspectives.
Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells.
Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) overexpression in tumors predicts worse overall survival in hepatocellular carcinoma.
Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment.
Aldo-keto reductase family 1 member C1 regulates the osteogenic differentiation of human ASCs by targeting the progesterone receptor.
Aldo-keto reductase inhibitors increase the anticancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia.
Aldose reductase (AKR1B) deficiency promotes phagocytosis in bone marrow derived mouse macrophages.
Cadherins as novel targets for anti-cancer therapy.
Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.
Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours.
Comparison of crystal structures of human type 3 3alpha-hydroxysteroid dehydrogenase reveals an "induced-fit" mechanism and a conserved basic motif involved in the binding of androgen.
Design and synthesis of polyhydroxy steroids as selective inhibitors against AKR1B10 and molecular docking.
Design, synthesis and evaluation of caffeic acid phenethyl ester-based inhibitors targeting a selectivity pocket in the active site of human aldo-keto reductase 1B10.
DNA repair pathway activation features in follicular and papillary thyroid tumors, interrogated using 95 experimental RNA sequencing profiles.
Down-regulation of aldo-keto reductase AKR1B10 gene expression by a phorbol ester via the ERK/c-Jun signaling pathway.
Drug evaluation: ADH-1, an N-cadherin antagonist targeting cancer vascularization.
Effect of nicotinamide on hepatic microsomal drug metabolising system in tumour-bearing rats and mice.
Emergence of the Dedifferentiated Phenotype in Hepatocyte-Derived Tumors in Mice: Roles of Oncogene-Induced Epigenetic Alterations.
Establishment and characterization of mouse mammary carcinoma cell lines expressing RET with a multiple endocrine neoplasia 2A mutation.
Gateways to clinical trials.
Genomic alterations in breast cancer patients in betel quid and non betel quid chewers.
Heat shock protein 90-? mediates aldo-keto reductase 1B10 (AKR1B10) protein secretion through secretory lysosomes.
High expression of AKR1B10 predicts low risk of early tumor recurrence in patients with hepatitis B virus-related hepatocellular carcinoma.
High expression of aldo-keto reductase 1B10 is an independent predictor of favorable prognosis in patients with hepatocellular carcinoma.
IDD388 Polyhalogenated Derivatives as Probes for an Improved Structure-Based Selectivity of AKR1B10 Inhibitors.
Identification of a role for serum aldo-keto reductase family 1 member B10 in early detection of hepatocellular carcinoma.
Improvement of chemosensitivity and inhibition of migration via targeting tumor epithelial-to-mesenchymal transition cells by ADH-1-modified liposomes.
Inhibition of human aldose reductase-like protein (AKR1B10) by ?- and ?-mangostins, major components of pericarps of mangosteen.
Inhibitors of aldehyde dehydrogenases of the 1A subfamily as putative anticancer agents: Kinetic characterization and effect on human cancer cells.
Inhibitors of type 5 17?-hydroxysteroid dehydrogenase (AKR1C3): Overview and structural insights.
Inhibitory effects of polyphenols isolated from Rhus verniciflua on Aldo-keto reductase family 1 B10.
Inhibitory Interplay of SULT2B1b Sulfotransferase with AKR1C3 Aldo-keto Reductase in Prostate Cancer.
Involvement of the aldo-keto reductase, AKR1B10, in mitomycin-c resistance through reactive oxygen species-dependent mechanisms.
Lack of functional and expression homology between human and mouse aldo-keto reductase 1C enzymes: implications for modelling human cancers.
LCRF-0006, a small molecule mimetic of the N-cadherin antagonist peptide ADH-1, synergistically increases multiple myeloma response to bortezomib.
Long-chain fatty acids inhibit human members of the aldo-keto reductase 1C subfamily.
Low expression of Aldo-keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma.
Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity.
Melphalan in regional chemotherapy for locally recurrent metastatic melanoma.
Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation.
Metabolic characteristics and enflurane defluorination of cytochrome P450-dependent monooxygenases in human hepatocellular carcinoma.
Methyl Jasmonate: Putative Mechanisms of Action on Cancer Cells Cycle, Metabolism, and Apoptosis.
Modulated expression of genes encoding estrogen metabolizing enzymes by G1-phase cyclin-dependent kinases 6 and 4 in human breast cancer cells.
Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-?-hydroxysteroid dehydrogenase (AKR1C3).
Murine aldo-keto reductase family 1 subfamily B: identification of AKR1B8 as an ortholog of human AKR1B10.
N-cadherin as a therapeutic target in cancer.
N-cadherin in neuroblastoma disease: expression and clinical significance.
Novel chemical scaffolds of the tumor marker AKR1B10 inhibitors discovered by 3D QSAR pharmacophore modeling.
Novel peptide mimetic small molecules of the HAV motif in N-cadherin inhibit N-cadherin-mediated neurite outgrowth and cell adhesion.
Overcoming drug resistance with functional mesoporous titanium dioxide nanoparticles combining targeting, drug delivery and photodynamic therapy.
Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker.
Overexpression of aldo-keto reductase 1C2 is associated with disease progression in patients with prostatic cancer.
Phase I Clinical Trial of Exherin (ADH-1) in Patients with Advanced Solid Tumors.
Potent and selective inhibition of the tumor marker AKR1B10 by bisdemethoxycurcumin: probing the active site of the enzyme with molecular modeling and site-directed mutagenesis.
Prenatal alcohol exposure alters phosphorylation and glycosylation of proteins in rat offspring liver.
Prognostic value of aldo-keto reductase family 1 member B10 (AKR1B10) in digestive system cancers: A meta-analysis.
Prospective Multicenter Phase II Trial of Systemic ADH-1 in Combination With Melphalan via Isolated Limb Infusion in Patients With Advanced Extremity Melanoma.
Proteomics detection of S100A6 in tumor tissue interstitial fluid and evaluation of its potential as a biomarker of cholangiocarcinoma.
Quantitative analysis of the human AKR family members in cancer cell lines using the mTRAQ/MRM approach.
Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice.
Regulation Network and Prognostic Significance of Aldo-Keto Reductase (AKR) Superfamily Genes in Hepatocellular Carcinoma.
Renal gene expression in embryonic and newborn diabetic mice.
Selective inhibition of human type-5 17?-hydroxysteroid dehydrogenase (AKR1C3) by baccharin, a component of Brazilian propolis.
Selective inhibition of the tumor marker AKR1B10 by antiinflammatory N-phenylanthranilic acids and glycyrrhetic acid.
Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid.
Selectivity determinants of inhibitor binding to the tumour marker human aldose reductase-like protein (AKR1B10) discovered from molecular docking and database screening.
SMAR1 regulates free radical stress through modulation of AKR1a4 enzyme activity.
Stimulation of N-cadherin-dependent neurite outgrowth by small molecule peptide mimetic agonists of the N-cadherin HAV motif.
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
Synthesis and structure-activity relationship of 2-phenyliminochromene derivatives as inhibitors for aldo-keto reductase (AKR) 1B10.
Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3.
Synthesis of non-prenyl analogues of baccharin as selective and potent inhibitors for aldo-keto reductase 1C3.
Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy against Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer Cells.
Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment.
The hop-derived compounds xanthohumol, isoxanthohumol and 8-prenylnaringenin are tight-binding inhibitors of human aldo-keto reductases 1B1 and 1B10.
The roles of AKR1C1 and AKR1C2 in ethyl-3,4-dihydroxybenzoateinduced esophageal squamous cell carcinoma cell death.
Therapeutic targeting of N-cadherin is an effective treatment for multiple myeloma.
Transcriptomic responses of cancerous and noncancerous human colon cells to sulforaphane and selenium.
Neuralgia
Novel peptide mimetic small molecules of the HAV motif in N-cadherin inhibit N-cadherin-mediated neurite outgrowth and cell adhesion.
Neuroblastoma
Synthesis and catabolism of gamma-hydroxybutyrate in SH-SY5Y human neuroblastoma cells: role of the aldo-keto reductase AKR7A2.
Non-alcoholic Fatty Liver Disease
Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis.
Obesity
[Aldehyde reductase activity and blood aldo-keto reductase spectrum in adolescents with neuroendocrine obesity].
Ovarian Neoplasms
Overexpression of aldo-keto reductase 1C2 as a high-risk factor in bladder cancer.
Pancreatic Neoplasms
?2-AR regulates the expression of AKR1B1 in human pancreatic cancer cells and promotes their proliferation via the ERK1/2 pathway.
ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
AKR1C enzymes sustain therapy resistance in paediatric T-ALL.
Prostatic Hyperplasia
AKR1B10 expression in benign prostatic hyperplasia and its related mechanism.
Prostatic Neoplasms
3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: Highly Potent and Selective Inhibitors of the Type 5 17-?-Hydroxysteroid Dehydrogenase AKR1C3.
AKR1C2 and AKR1C3 mediated prostaglandin D2 metabolism augments the PI3K/Akt proliferative signaling pathway in human prostate cancer cells.
Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer.
Inhibitory Interplay of SULT2B1b Sulfotransferase with AKR1C3 Aldo-keto Reductase in Prostate Cancer.
PTHrP stimulates prostate cancer cell growth and upregulates aldo-keto reductase 1C3.
Roles of aldo-keto reductase 1B10 and 1C3 and ATP-binding cassette transporter in docetaxel tolerance.
Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.
Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolism.
Riboflavin Deficiency
Effects of riboflavin deficiency on lipid peroxidation of rat liver microsomes.
Lipid metabolism in riboflavin-deficient rats. 2. Mitochondrial fatty acid oxidation and the microsomal desaturation pathway.
Sarcoma, Yoshida
Effect of nicotinamide on hepatic microsomal drug metabolising system in tumour-bearing rats and mice.
Seizures
Diet composition, alcohol utilization, and dependence.
Sepsis
Aldose reductase (AKR1B) deficiency promotes phagocytosis in bone marrow derived mouse macrophages.
Squamous Cell Carcinoma of Head and Neck
Increased salivary AKR1B10 level: Association with progression and poor prognosis of oral squamous cell carcinoma.
Stomach Neoplasms
Acquisition of doxorubicin resistance facilitates migrating and invasive potentials of gastric cancer MKN45 cells through up-regulating aldo-keto reductase 1B10.
Aldo-keto reductase 1B10 promotes development of cisplatin resistance in gastrointestinal cancer cells through down-regulating peroxisome proliferator-activated receptor-?-dependent mechanism.
[Expression of aldo-keto reductase family 1 member B10 in gastric cancer tissues and its clinical significance].
Stroke
Effect of C7 Modifications on Benzothiadiazine-1,1-dioxide Derivatives on Their Inhibitory Activity and Selectivity toward Aldose Reductase.
Tardive Dyskinesia
Extrapyramidal disorders: a possible underlying mechanism.
Thiamine Deficiency
Acceleration of ethanol metabolism by past thiamine deficiency.
Tuberculosis
Biotransformation and bioactivation reactions - 2015 literature highlights.
Drug metabolism in experimental tuberculosis: I. Changes in hepatic and pulmonary monooxygenase activities due to infection.
Uremia
Effect of uremia on rates of ethanol disappearance from the blood and on the activities of the ethanol-oxidizing enzymes.
Urinary Bladder Neoplasms
Aldo-keto reductase 1C1 induced by interleukin-1? mediates the invasive potential and drug resistance of metastatic bladder cancer cells.
Uterine Cervical Neoplasms
Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer.
Uterine Diseases
Enzymes of the AKR1B and AKR1C Subfamilies and Uterine Diseases.
Vitamin A Deficiency
Effects of vitamin A deficiency on rat liver alcohol dehydrogenase expression and alcohol elimination rate in rats.